Hims & Hers Health, Stock Drops and Weight-Loss Business

Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight-loss drugs.
Hims & Hers Health 4Q Revenue Surges on Boost From Weight-Loss Treatments
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged 69% to nearly $1.48 billion in 2024 from $872 million in 2023.
Hims Stock Drops on Uncertainty About Weight-Loss Business
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said that it will soon stop selling some compound weight-loss drugs.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in the space is a decision by drugmaker Eli Lilly on Tuesday to cut prices of Zepbound, another weight-loss drug.
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS) and Novo Nordisk (NVO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...
Hims & Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Seeking Alpha4d
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. I provide multiple perspectives in this article, offering readers different ...
WPTV-TV1h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Why Hims & Hers Health Stock Is Skyrocketing Today
Shares of Hims & Hers Health Inc (NYSE: HIMS) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m ...